Regulus Therapeutics appoints Neil W. Gibson as CSO

Monday, April 18, 2011 01:09 PM

Regulus Therapeutics, a biopharmaceutical company that discovers and develops new medicines targeting microRNAs, has appointed Neil Gibson, Ph.D., as its chief scientific officer. 

Gibson joins Regulus from the oncology research unit at Pfizer in California where he most recently held positions as chief scientific officer and oncology therapeutic area head. Prior to Pfizer, he held positions at OSI Pharmaceuticals including chief scientific officer. Gibson's industry experience has also included service as a director for cancer research in the department of cancer and osteoporosis for Bayer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs